SCHEMBL21805908

SCHEMBL21805908

Nc1nc(OCc2ccccc2)ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.50
MCL1 Q07820 1/20 0.47
BAK1 Q16611 1/20 0.47
ALKBH1 Q13686 1/20 0.44
MAP4K4 O95819 1/20 0.44
ALDH1A1 P00352 1/20 0.44
NR4A1 P22736 1/20 0.44
NR4A2 P43354 1/20 0.44
NR4A3 Q92570 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
MGMT P16455 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CCNA1 P78396 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LTA4H P09960 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22289031 0.86 LMNA (0.47) MCL1BAK1ALDH1A1MEN1KMT2A
SCHEMBL31159061 0.83 MCL1 (0.64) FOLH1MCL1BAK1ALKBH1ALDH1A1
SCHEMBL31727623 0.83 MCL1 (0.64) FOLH1MCL1BAK1ALKBH1ALDH1A1
SCHEMBL27827736 0.82 NOX1 (0.56) FOLH1MCL1BAK1ALKBH1ALDH1A1
SCHEMBL31388800 0.82 MCL1 (0.53) FOLH1MCL1BAK1ALKBH1ALDH1A1
SCHEMBL1680784 0.80 MAPT (0.50) ALDH1A1NAPRT
SCHEMBL29424833 0.79 LTA4H (0.49) CDK1CCNB1MGMTCCNA2CDK2
SCHEMBL2191517 0.79 LTA4H (0.49) CDK1CCNB1MGMTCCNA2CDK2
SCHEMBL19329183 0.78 MCL1 (0.59) FOLH1MCL1BAK1ALKBH1GRM5
SCHEMBL1680324 0.78 NAPRT (0.42) FOLH1ALDH1A1NAPRTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019383-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2025-01-16 US disclosed
CN-119039288-A Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication VIIV保健英国第五有限公司 2024-11-29 CN disclosed
US-12129255-B2 Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2024-10-29 US disclosed
CN-114245795-B Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication VIIV保健英国第五有限公司 2024-08-06 CN disclosed
US-11919897-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2024-03-05 US disclosed
EP-3986561-B1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2024-02-14 EP disclosed
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2023-11-09 US disclosed
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2023-11-09 US disclosed
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2023-11-09 US disclosed
US-20230149408-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2023-05-18 US disclosed
EP-3853228-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-07-28 EP disclosed
EP-3849982-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-07-21 EP disclosed
WO-2021064571-A1 N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-04-08 WO disclosed
WO-2021064571-A1 N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-04-08 WO disclosed
WO-2020254985-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-12-24 WO disclosed
WO-2020254985-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-12-24 WO disclosed
WO-2020157692-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-08-06 WO disclosed
WO-2020157692-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-08-06 WO disclosed
WO-2020058844-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-03-26 WO disclosed
WO-2020053811-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149408-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION POLR2H, POLR2E, EIF2AK2 FOLH1 3928/4885MCL1 1046/4885BAK1 2367/4885
US-20250019383-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION TYMP, TYMS, DPYD FOLH1 2606/4885MCL1 2944/4885BAK1 711/4885
US-11919897-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H FOLH1 3754/4885MCL1 909/4885BAK1 1366/4885
US-12129255-B2 Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication TYMP, TYMS, DPYD FOLH1 2606/4885MCL1 2944/4885BAK1 711/4885
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H FOLH1 3754/4885MCL1 909/4885BAK1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.